

Risk Adjustment Coding and HCC Guide

Simplifying the RA/HCC systems and optimization opportunities





Contents

Introduction Risk Adjustment Data Files	
Chapter 1. Risk Adjustment Basics	
Key Terms	
Payment Methodology	
Purpose of Risk Adjustment	
Risk-Adjustment Characteristics	
Risk Adjustment Beyond Medicare Advantage	
Comparison of Plans	
Health and Human Services	
Chronic Illness and Disability Payment Systems	
Diagnosis Related Groups	
HCC Compared to MS-DRG	
Programs of All-inclusive Care for the Elderly	
End Stage Renal Disease	
RxHCC	
Payment	
Chapter 2. Coding and Documentation	
Medical Record Documentation	
General Standards	
Acceptable Sources	
Signature Issues	
Coding Guidelines	
ICD-10-CM Guidelines	
Fee for Service vs. Risk-Adjustment Coding	
Linking Diagnoses	
CMS Participant Guide Excerpts	
On-going Chronic Conditions	
Recapture	
Code Set Updates	
Coding Guidelines Discussion	
Tools Clinical Documentation Integrity	
Coding Scenarios with RAF Values	
Coding Scenario 1—CMS-HCC Model	
Coding Scenario 2—CMS-HCC Model Coding Scenario 3—CMS-HCC Model	
Coding Scenario 4—CMS-HCC Model	
Coding Scenario 5—ESRD-HCC Model	
Clinical Documentation Improvement Education	
ICD-10-CM	
Queries	
Internal Risk Adjustment Policies	
Documentation Requirements	
Chapter 3. Audits and Quality Improvement	
Medicare Advantage Risk Adjustment Data Validation	
Audit Scenarios	
Audit Scenario 1—CMS-HCC Model	
Audit Scenario 1 Rationale—CMS-HCC Model	
Audit Scenario 2—CMS-HCC Model	
Audit Scenario 2 Rationale—CMS-HCC Model	
Audit Scenario 3—CMS-HCC Model	48

Audit Scenario 3 Rationale—CMS-HCC Model	51
Audit Scenario 4—CMS-HCC Model	52
Audit Scenario 4 Rationale—CMS-HCC Model	53
Audit Scenario 5—ESRD-HCC Model	54
Audit Scenario 5 Rationale—ESRD-HCC Model	57
RAD-V Audit Steps	
Medicare Advantage Risk Adjustment Data Validation—Recovery Audit Contractors	
Health and Human Services Risk Adjustment Data Validation	
Health Effectiveness Data and Information Set	
Medicare STAR Ratings	
Internal Care and Quality Improvement Audits	
Mock Audit Protocol	
Chapter 4. CY2023 CMS-HCC Model Category V24	
Disease Coefficient Relative Factors and Hierarchies for Continuing Enrollees Community	
and Institutional Beneficiaries with Midyear Final ICD-10-CM Mappings	
Relative Factors for Continuing Enrollees	
Medicaid and Originally Disabled Interactions	
Disease Interactions	
Disabled/Disease Interactions	523
Payment HCC Counts	
Relative Factors for Aged and Disabled New Enrollees	
Relative Factors for New Enrollees in Chronic Condition Special Needs Plans (C-SNPs)	
Chapter 5. CY2023 CMS RxHCC Model Category V08	
Midyear Final ICD-10-CM Mapping, Hierarchies, and Disease Coefficients	
Demographic Relative Factors for Continuing Enrollees	
Non-Aged Disease Interactions	
Demograhic Relative Factors for New Enrollees, Non-Low Income	
Demograhic Relative Factors for New Enrollees, Low Income	
Demograhic Relative Factors for New Enrollees, Institutional	

Introduction

The traditional fee-for-service payment model has been widely used since the 1930s when health insurance plans initially gained popularity within the United States. In this payment model, a provider or facility is compensated based on the services provided. This payment model has proven to be very expensive. Closer attention is being paid to healthcare spending versus outcomes and quality of care and this has been compared to the healthcare spending of other nations. This has caused a need to develop a system to evaluate the care being given.

In the 1970s, Medicare began demonstration projects that contracted with health maintenance organizations (HMO) to provide care for Medicare beneficiaries in exchange for prospective payments. In 1985, this project changed from demonstration status to a regular part of the Medicare program, Medicare Part C. The Balanced Budget Act (BBA) of 1997 named Medicare's Part C managed care program Medicare+Choice, and the Medicare Prescription Drug, Improvement and Modernization Act (MMA) of 2003 again renamed it to Medicare Advantage (MA).

Medicare is one of the world's largest health insurance programs, and about one-third of the beneficiaries on Medicare are enrolled in an MA private healthcare plan. Due to the great variance in the health status of Medicare beneficiaries, risk adjustment provides a means of adequately compensating those plans with large numbers of seriously ill patients while not overburdening other plans that have healthier individuals. MA plans have been using the Hierarchical Condition Category (HCC) risk-adjustment model since 2004.

The primary purpose of a risk-adjustment model is to predict (on average) the future healthcare costs for specific consortiums enrolled in MA health plans. The Centers for Medicare and Medicaid Services (CMS) is then able to provide capitation payments to these private health plans. Capitation payments are an incentive for health plans to enroll not only healthier individuals but those with chronic conditions or who are more seriously ill by removing some of the financial burden.

The MA risk-adjustment model uses HCCs to assess the disease burden of its enrollees. HCC diagnostic groupings were created after examining claims data so that enrollees with similar disease processes, and consequently similar healthcare expenditures, could be pooled into a larger data set in which an average expenditure rate could be determined. The medical conditions included in HCC categories are those that were determined to most predictably affect the health status and healthcare costs of any individual.

Section 1343 of the Affordable Care Act (ACA) of 2010 provides for a risk-adjustment program for non-Medicare Advantage plans that are available in online insurance exchange marketplaces. Beginning in 2014, commercial insurances were able to potentially mitigate increased costs for the insurance plan and increased premiums for higher-risk populations, such as those with chronic illnesses, by using a risk-adjustment model. The risk-adjustment program developed for use by non-Medicare plans is maintained by the Department of Health and Human Services (HHS). This model also uses HCC diagnostic groupings; however, this set of HCCs differs from the CMS-HCCs to reflect the differences in the populations served by each healthcare plan type.

This publication will cover the following:

- History and purpose of risk-adjustment factor (RAF)
- Key terms definitions
- Acceptable provider types
- Payment methodology and timeline
- Coding and documentation
- Tools for risk adjustment
- Coding scenarios
- Guidance for developing internal risk adjustment coding polices
- Audits
- Healthcare Effectiveness Data and Information Set (HEDIS)
- Risk adjustment model tables

Coding is an increasingly complex business. The movement from the fee-for-service payment model to more qualitative models has increased rapidly since 2004. The demand for quality-focused payment models has gained more attention since the ACA introduced a risk-adjustment model to the online insurance exchange marketplace plans in 2017. Coding staff must have knowledge of risk- adjustment practices in this rapidly changing environment. This book provides conceptual and practical knowledge of risk adjustment to coders, coding managers, medical staff, clinical documentation improvement (CDI) professionals, payers, educators, and students. The goal is to develop and enrich the knowledge of the user's understanding of this payment methodology.

Chapter 1. Risk Adjustment Basics

The need to track and report disease and causes of death was recognized in the 18th century. The various popular methodologies were compiled over the course of the First through Fifth International Statistical Institute Conferences in the 20th century; during the Sixth International Conference, the World Health Organization (WHO) was tasked with revising and maintaining the classifications of disease and death. In the 1930s health insurance coverage gained popularity. Many labor groups and companies started offering this type of benefit to their employees. In 1966, the American Medical Association (AMA) published the first edition of the Current Procedural Terminology (CPT[®]) to standardize the reporting of surgical procedures. This framework created the fee-for-service payment model, which is currently used.

The fee-for-service model, however, does not account for acuity or morbidity of its patients. A medically complex, chronically ill patient's healthcare provider would receive the same reimbursement for the same procedure done on a healthy patient.

In 1997, the Balanced Budget Act mandated that Medicare begin allowing participants to choose between traditional Medicare and managed Medicare plans (now Medicare Advantage), which would incorporate the risk-adjustment payment methodology no later than January 2000. Initially, these managed Medicare plans were paid a fixed dollar amount to care for Medicare members. In 2007, these MA plans were based 100 percent on risk adjustment. This better allocates resources to populations of medically needy patients.

Key Terms

Hierarchical condition categories (HCC). Groupings of clinically similar diagnoses in each risk-adjustment model. Conditions are categorized hierarchically and the highest severity takes precedence over other conditions in a hierarchy. Each HCC is assigned a relative factor that is used to produce risk scores for Medicare beneficiaries, based on the data submitted in the data collection period.

Medicare Advantage (MA) plan. Sometimes called "Part C" or "MA plans," offered by private companies approved by Medicare. If a Medicare Advantage plan is selected by the enrollee, the plan will provide all of Part A (hospital insurance) and Part B (medical insurance) coverage. Medicare Advantage plans may offer extra coverage, such as vision, hearing, dental, and/or health and wellness programs. Most include Medicare prescription drug coverage (Part D).

Risk-adjustment factor (RAF). Risk score assigned to each beneficiary based on his or her disease burden, as well as demographic factors.

Sweeps. Submission deadline for risk adjustment data that occurs three times annually: January, March, and September. Generally, claims continue to be accepted for two weeks after the deadline.

Payment Methodology

Purpose of Risk Adjustment

Risk adjustment allows CMS to pay plans for the risk of the beneficiaries they enroll, instead of an average amount for Medicare beneficiaries. By risk adjusting plan payments, CMS is able to make appropriate and accurate payments for enrollees with differences in expected costs. Risk adjustment is used to adjust bidding and payment based on the health status and demographic characteristics of an enrollee. Risk scores measure individual beneficiaries' relative risk and risk scores are used to adjust payments for each beneficiary's expected expenditures. By risk adjusting plan bids, CMS is able to use standardized bids as base payments to plans.

The primary purpose of a risk-adjustment model is to predict future healthcare costs for specific consortiums enrolled in MA health plans based on current risk factors associated with the covered patient population. CMS is then able to provide capitation payments to these private health plans. Capitation payments that are calculated based on an entire risk pool incentivize health plans to enroll not only healthier individuals but those with chronic conditions or who are more seriously ill by removing some of the financial burden.

The MA risk-adjustment model uses HCCs to assess the disease burden of its enrollees. The HCC diagnostic groupings were created after examining claims data so that enrollees with similar disease processes, and consequently similar healthcare expenditures, could be pooled into a larger data set in which an average expenditure rate could be determined. The medical conditions included in HCC categories are those that were determined to most predictably affect the health status and healthcare costs of any individual.

Hierarchical condition categories (HCC) were first used in 2004 to set capitated payments for private health plans caring for Medicare beneficiaries. The term "risk adjustment" is often used to describe what HCCs do. HCCs predict healthcare resource consumption of individuals. HCC scores are used to "risk adjust" payments to a health plan based on the level of

Coding Scenario 4—CMS-HCC Model

1	Patient: Joe Holmes	DOS: 01/23/2021	Ins: Medicare
	DR: Robert Jacobs, M.D.	Age: 78 years	

CC:

Annual wellness visit

Subjective

Patient seen for annual wellness visit. He had a colonoscopy in 2016. He refuses the flu vaccine. Patient is compliant with DM management. Patient complains of wound on his leg for 10 days. Med list reviewed in EMR module. No changes to P/F/S hx from last AWV. Patient regularly sees oncology. Today wants to discuss other treatment options. PHQ-9 score is 4. Upset about mets.

Objective

Alert, no acute distress, HEENT:NC, pupils equal, round, sclera white, conj. clear, external nose WNL, on O2 nasal cannula, no lesions, external ear normal, lips/mouth free of lesions, Neuro: no tremor, Neck: trachea midline normal appearance, MS: normal gait and posture, Ext: no edema or clubbing, poss claudication, ulcer noted on distal left calf r/o venous stasis, skin: No rash or lesions, L diminished bs, no wheezing, Hrrr no m/r/c, Abd soft nt +bs.

Assessment

Poss claudication/leg ulcer, bone and lymph mets, prostate ca, DM, IBS, resp insuff syndrome.

Plan

Get ABI—r/o claudication w/ ulcer. DAL patient needs to speak to oncologist about tx for mets and continue "watchful waiting" on prostate ca. Patient is compliant on DM regime, continue. Refer to GI for IBS. Dependent on home O₂ increase 5L.

HCC Category	ICD-10	-CM Code Description	RAF Value	Validated by Current Documentation	Improved Documentation
HCC 12*	C61	Malignant neoplasm of prostate	0.150	Yes	Yes
HCC 8	C79.51	Secondary malignant neoplasm of bone	2.659	Yes	Yes
HCC 10*	C77.9	Secondary and unspecified malignant neoplasm of lymph node, unspecified	0.675	Yes	Yes
HCC 108	173.9	Peripheral vascular disease, unspecified	0.288	No	Yes
HCC 18	E11.51	Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene	0.302	No	Yes
HCC 59	F32.1	Major depressive disorder, single episode, moderate	0.309	No	Yes
HCC 84	J96.11	Chronic respiratory failure with hypoxia	0.282	No	Yes
Demographics	78-year	-old, male, not Medicaid eligible	0.473	Yes	Yes
D1	1 Payment HCC		_	Yes	Yes
D5	5 Paym	ent HCCs	0.042	No	Yes
Total RAF				3.132	4.355

*Trumping logic applies

The provider should be queried for major depressive disorder based on the PHQ-9 score of 4, scores in the range of 0-4 indicate minimal or no depression.

The provider should also be queried for chronic respiratory failure and underlying condition. The patient is noted to be dependent on oxygen and the oxygen is being increased. The documentation of "resp insuff syndrome" cannot be indexed in ICD-10-CM, and respiratory insufficiency is a symptom, reported with code R06.89 Other abnormalities of breathing.

ICD-10-CM code I73.9 Peripheral vascular disease, unspecified, is not validated in the encounter notes due to the provider documenting that claudication is possible. The provider should be queried for validation of this condition if it exists. Until the peripheral vascular disease is documented as a valid condition, reporting E11.51 is also not appropriate. *AHA Coding Clinic*, second quarter, 2018, page 7 states the following, "Peripheral arteriosclerosis, peripheral vascular disease and peripheral arterial disease in a diabetic patient should be linked and coded as "diabetic peripheral angiopathy"." However, this link cannot be made when the documentation indicates uncertainty as to the peripheral vascular disease.

The CMS-HCC trumping logic applies to HCC 12 and HCC 10. Conditions in HCC 8 trump conditions in HCC 10 and HCC 12. Therefore, in this example, the values of HCC 10 and HCC 12 would not be factored into the patient's risk score.

Chapter 3. Audits and Quality Improvement

A chart audit is a detailed review of the medical record to determine if the services rendered match the services reported. In risk adjustment, this is ensuring that conditions reported are supported by valid medical records. Most often, audits are performed to ensure accuracy and compliance; however, quality improvement measure audits are increasingly popular.

It is advisable to regularly audit the documentation being used as well as the coding for risk adjustment to ensure compliance.

Step 1

Determine who will perform the audit. An internal audit is typically performed by coding staff within the practice that are proficient in coding and interpreting payer guidelines. Depending upon the size of the practice and the number of services provided annually, a compliance department with full-time auditors may be established. If not, the person performing the audit should not audit claims that he or she coded.

Step 2

Define the scope of the audit. Determine what types of services to include in the review. Use the most recent Office of Inspector General (OIG) Work Plan, recovery audit contractor (RAC) issues, and third-party payer provider bulletins, which will help identify areas that can be targeted for upcoming audits. Review the OIG Work Plan, which is now a web-based work plan updated monthly rather than yearly, to determine if there are issues of concern that apply to the practice. Determine specific coding issues or claim denials that are experienced by the practice. The frequency of coding or claims issues and potential effect on reimbursement or potential risk can help prioritize which areas should be reviewed. Services that are frequently performed or have complex coding and billing issues should also be reviewed, as the potential for mistakes or impact to revenue could be substantial.

Step 3

Determine the type of audit to be performed and the areas to be reviewed. Once the area of review is identified, careful consideration should be given to the type of audit performed. Reviews can be prospective or retrospective. If a service is new to the practice, or if coding and billing guidelines have recently been revised, it may be advisable to create a policy stating that a prospective review is performed on a specified number of claims as part of a compliance plan. The audit should include ensuring the medical record coded meets administrative requirements, such as patient name and date of service are on the record, accuracy of diagnosis codes, compliance of any queries generated, and whether the source document supports code assignment.

Step 4

Assemble reference materials. Reference materials, such as current editions of coding manuals and Centers for Medicare and Medicaid Services (CMS) or other third-party policies pertinent to the services being reviewed, should be collected.

Step 5

Develop customized data capture tools. Use an audit worksheet, see example on page 83. Audit worksheets can aid in the audit process. They help verify that signatures were obtained and that patient identifying information (e.g., complete name, date of birth) is correct.

Step 6

Develop a reporting mechanism for findings. Once the audit is complete, written recommendations should be made. The recommendations can include conducting a more frequent focused audit, implementing improved documentation templates, or conducting targeted education on ICD-10-CM coding. Each practice should have benchmarks set up that all providers must meet. For example, if 10 charts are reviewed, 90 percent must be correct. It is also important to identify claims that may need to be corrected or payments that need to be refunded to the payer.

Step 7

Determine recommendations and corrective actions. The next step is to schedule meetings with the providers to provide feedback, recommendations, and education. Typically it works best to meet with a provider on an individual basis and have his or her audit results and charts available as examples so that they can be reviewed and discussed. The provider should be given the opportunity to explain the rationale behind his or her coding, and perhaps even provide additional information to help the coder further understand a particular clinical term. Allowing the provider to give feedback also helps build a better auditor-provider relationship. This relationship may make the provider feel comfortable enough with the auditor to ask questions about future coding issues, instead of reporting incorrect codes to payers. A word to the wise, when discussing a coding error with a provider, it is a good idea to have a copy of the official source document supporting discussion of the error.

Chapter 4. CY2023 CMS-HCC Model Category V24

Disease Coefficient Relative Factors and Hierarchies for Continuing Enrollees Community and Institutional Beneficiaries with Midyear Final ICD-10-CM Mappings

According to the Announcement of Calendar Year (CY) 2023 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, published on April 4, 2022, for CY 2023, CMS will continue to calculate 100 percent of the risk score using the 2020 CMS-HCC model, which began phasing in with CY 2020 payment as described in Part I of the CY 2020 Advance Notice.

ICD-10-CM Code	ICD-10-CM Code Description	V24 CMS-HCC	V24 CMS-HCC Disease Group	V24 CMS-HCC Hierarchies	Community, NonDual, Aged	Community, NonDual, Disabled	Community, FBDual, Aged	Community, FBDual, Disabled	Community, PBDual, Aged	Community, PBDual, Disabled	Institutional
AØ1.Ø3	Typhoid pneumonia	115	Pneumococcal Pneumonia, Empyema, Lung Abscess		0.13	0	0.258	0	0.093	0.082	0.156
AØ1.Ø4	Typhoid arthritis	39	Bone/Joint/Muscle Infections/ Necrosis		0.401	0.378	0.558	0.682	0.443	0.435	0.401
AØ1.Ø5	Typhoid osteomyelitis	39	Bone/Joint/Muscle Infections/ Necrosis		0.401	0.378	0.558	0.682	0.443	0.435	0.401
AØ2.1	Salmonella sepsis	2	Septicemia, Sepsis, Systemic Inflammatory Response Syndrome/ Shock		0.352	0.414	0.453	0.53	0.316	0.297	0.324
AØ2.22	Salmonella pneumonia	115	Pneumococcal Pneumonia, Empyema, Lung Abscess		0.13	0	0.258	0	0.093	0.082	0.156
AØ2.23	Salmonella arthritis	39	Bone/Joint/Muscle Infections/ Necrosis		0.401	0.378	0.558	0.682	0.443	0.435	0.401
AØ2.24	Salmonella osteomyelitis	39	Bone/Joint/Muscle Infections/ Necrosis		0.401	0.378	0.558	0.682	0.443	0.435	0.401
AØ6.5	Amebic lung abscess	115	Pneumococcal Pneumonia, Empyema, Lung Abscess		0.13	0	0.258	0	0.093	0.082	0.156
AØ7.2	Cryptosporidiosis	6	Opportunistic Infections		0.424	0.74	0.572	0.803	0.318	0.658	0.534
A2Ø.2	Pneumonic plague	115	Pneumococcal Pneumonia, Empyema, Lung Abscess		0.13	0	0.258	0	0.093	0.082	0.156
A2Ø.7	Septicemic plague	2	Septicemia, Sepsis, Systemic Inflammatory Response Syndrome/ Shock		0.352	0.414	0.453	0.53	0.316	0.297	0.324
A21.2	Pulmonary tularemia	115	Pneumococcal Pneumonia, Empyema, Lung Abscess		0.13	0	0.258	0	0.093	0.082	0.156
A22.1	Pulmonary anthrax	115	Pneumococcal Pneumonia, Empyema, Lung Abscess		0.13	0	0.258	0	0.093	0.082	0.156
A22.7	Anthrax sepsis	2	Septicemia, Sepsis, Systemic Inflammatory Response Syndrome/ Shock		0.352	0.414	0.453	0.53	0.316	0.297	0.324
A26.7	Erysipelothrix sepsis	2	Septicemia, Sepsis, Systemic Inflammatory Response Syndrome/ Shock		0.352	0.414	0.453	0.53	0.316	0.297	0.324
A31.Ø	Pulmonary mycobacterial infection	6	Opportunistic Infections		0.424	0.74	0.572	0.803	0.318	0.658	0.534
A31.2	Disseminated mycobacterium avium-intracellulare complex (DMAC)	6	Opportunistic Infections		0.424	0.74	0.572	0.803	0.318	0.658	0.534
A32.7	Listerial sepsis	2	Septicemia, Sepsis, Systemic Inflammatory Response Syndrome/ Shock		0.352	0.414	0.453	0.53	0.316	0.297	0.324
A36.81	Diphtheritic cardiomyopathy	85	Congestive Heart Failure		0.331	0.447	0.371	0.486	0.336	0.422	0.203
A39.1	Waterhouse-Friderichsen syndrome	23	Other Significant Endocrine and Metabolic Disorders		0.194	0.378	0.211	0.299	0.174	0.319	0.379
A39.2	Acute meningococcemia	2	Septicemia, Sepsis, Systemic Inflammatory Response Syndrome/ Shock		0.352	0.414	0.453	0.53	0.316	0.297	0.324

Chapter 5. CY2023 CMS RxHCC Model Category V08

Midyear Final ICD-10-CM Mapping, Hierarchies, and Disease Coefficients

A312 Disseminated mycobacterium avium-intracellulare complex (DMAC) 5 Opportunistic Infections 0.337 0.409 0.335 0.222 0.210 A36.81 Diphthertic cardiomycotty 186 Heart Failure 187 0.210 0.148 0.220 0.155 0.234 A39.1 Waterhouse-Friderichsen syndrome 43 Pitutary, Adrenal Gland, and Other Friderich and Metabolic Disorders 0.062 0.165 0.000 <th></th>										
A31.0 Pulmonary mycobacterial infection S Opportunistic Infections 0.337 0.409 0.335 0.262 0.270 A31.2 Disseminated mycobacterium subministed intracellular complex (DMAC) S Opportunistic Infections 0.337 0.409 0.335 0.262 0.270 A38.01 Diphtheritic cardiomyopathy 186 Heart Failure 187 0.210 0.148 0.020 0.148 0.020 0.010 0.000 <t< th=""><th>ICD-10-CM Code</th><th>ICD-10-CM Code Description</th><th>V08 RxHCC</th><th>V24 CMS-HCC Description</th><th>V08 RxHCC Hierarchy</th><th>Community Non-Low Income, Age>=65</th><th>Community Non-Low Income, Age<65</th><th>Community Low Income, Age>=65</th><th>Community Low Income, Age<65</th><th>Institutional</th></t<>	ICD-10-CM Code	ICD-10-CM Code Description	V08 RxHCC	V24 CMS-HCC Description	V08 RxHCC Hierarchy	Community Non-Low Income, Age>=65	Community Non-Low Income, Age<65	Community Low Income, Age>=65	Community Low Income, Age<65	Institutional
A312 Disseminated mycobacterium avium-intracellulare complex (DMAC) 5 Opportunistic Infections 0.337 0.409 0.335 0.222 0.210 A36.81 Diphthertic cardiomycotatiy 186 Heart Failure 187 0.210 0.148 0.221 0.149 0.223 0.155 0.234 A31.01 Creutrfeld-Lakob disease 112 Dementia, Except Alzheimer's Disease 0.096 0.038 0.000 <t< td=""><td>AØ7.2</td><td>Cryptosporidiosis</td><td>5</td><td>Opportunistic Infections</td><td></td><td>0.337</td><td>0.409</td><td>0.335</td><td>0.262</td><td>0.270</td></t<>	AØ7.2	Cryptosporidiosis	5	Opportunistic Infections		0.337	0.409	0.335	0.262	0.270
avum-intracellulare complex (DMAC) interaction interaction interaction A36.81 Diphtheritic cardiomyopatty 186 Heart Falure 187 0.210 0.148 0.270 0.195 0.234 A39.1 Watchouse Friderichisen syndrome 38 Pittutary, Adrenal Giand, and OtherEndocrine and Metabolic Disorders 0.062 0.063 0.000 <td>A31.Ø</td> <td>Pulmonary mycobacterial infection</td> <td>5</td> <td>Opportunistic Infections</td> <td></td> <td>0.337</td> <td>0.409</td> <td>0.335</td> <td>0.262</td> <td>0.270</td>	A31.Ø	Pulmonary mycobacterial infection	5	Opportunistic Infections		0.337	0.409	0.335	0.262	0.270
A39.1 Waterhouse-Friderichsen syndrome 43 Pitutary, Adrenal Gland, and OtherEndocrine and Metabolic Disorders 0.062 0.165 0.000 0.111 0.068 A81.00 Creutzfeldt-Jakob disease 112 Dementia, Except Alzheimer's Disease 0.096 0.038 0.000 0.038	A31.2		5	Opportunistic Infections		0.337	0.409	0.335	0.262	0.270
OtherEndocrine and Mietabolic Diorders O Feature A81.80 Creutzfeldt-Jakob disease 112 Dementia, Except Alzheimer's Disease 0.096 0.038 0.000 0.000 0.000 A81.81 Variant Creutzfeldt-Jakob disease 112 Dementia, Except Alzheimer's Disease 0.096 0.038 0.000 0.000 0.000 A81.9 Order Seise multford 112 Dementia, Except Alzheimer's Disease 0.096 0.038 0.000 0.000 0.000 A81.2 Progesive multforcal leukoencephalopathy 112 Dementia, Except Alzheimer's Disease 0.096 0.038 0.000 0.000 0.000 A81.82 Gerstmann-Straussler-Scheinker syndrome 112 Dementia, Except Alzheimer's Disease 0.096 0.038 0.000 0.000 0.000 A81.82 Gerstmann-Straussler-Scheinker syndrome 112 Dementia, Except Alzheimer's Disease 0.096 0.038 0.000 0.000 0.000 A81.82 Herpes simplex myelitis 155 Spinal Cord Disorders 0.094 0.080 0.053 0.000	A36.81	Diphtheritic cardiomyopathy	186	Heart Failure	187	0.210	0.148	0.270	0.195	0.234
A81.91 Variant Creutzfeldt-Jakob disease 112 Dementia, Except Alzheimer's Disease 0.096 0.038 0.000 0.000 A81.9 Other Creutzfeldt-Jakob disease 112 Dementia, Except Alzheimer's Disease 0.096 0.038 0.000 0.000 A81.1 Subacute sclerosing panencephalitis 112 Dementia, Except Alzheimer's Disease 0.096 0.038 0.000 0.000 0.000 A81.2 Progressive multifical leukoencephalopathy 112 Dementia, Except Alzheimer's Disease 0.096 0.038 0.000 0.000 0.000 A81.82 Gerstmam-Straussler-Scheinker syndrome 112 Dementia, Except Alzheimer's Disease 0.096 0.038 0.000 0.000 0.000 A81.89 Other anylical virus infection of central nervous system, unspecified 112 Dementia, Except Alzheimer's Disease 0.096 0.038 0.000 0.000 0.000 B01.12 Varicella myelitis 155 Spinal Cord Disorders 0.094 0.080 0.030 0.000 0.000 B02.21 Postherpetic nyneuropathy <	A39.1	Waterhouse-Friderichsen syndrome	43			0.062	0.165	0.000	0.141	0.068
A81.99 Other Creutzfeldt-Jakob disease 112 Dementia, Except Alzheimer's Disease 0.096 0.038 0.000 0.000 A81.1 Subacute sclerosing panencephalitis 112 Dementia, Except Alzheimer's Disease 0.096 0.038 0.000 0.000 0.000 A81.2 Progressive multifocant 112 Dementia, Except Alzheimer's Disease 0.096 0.038 0.000 0.000 0.000 A81.82 Gerstmann-Strausder-Scheinker syndrome 112 Dementia, Except Alzheimer's Disease 0.096 0.038 0.000 0.000 0.000 A81.83 Fatal familial insomnia 112 Dementia, Except Alzheimer's Disease 0.096 0.038 0.000 0.000 0.000 A81.9 Atypical virus infection of central nervous system 112 Dementia, Except Alzheimer's Disease 0.096 0.038 0.000 0.000 0.000 B08.21 Perse simplex myellitis 155 Spinal Cord Disorders 0.094 0.080 0.033 0.000 0.018 B02.21 Posthereptic tyeninial nervalgia 10.124 <td>A81.ØØ</td> <td>Creutzfeldt-Jakob disease, unspecified</td> <td>112</td> <td>Dementia, Except Alzheimer's Disease</td> <td></td> <td>0.096</td> <td>0.038</td> <td>0.000</td> <td>0.000</td> <td>0.000</td>	A81.ØØ	Creutzfeldt-Jakob disease, unspecified	112	Dementia, Except Alzheimer's Disease		0.096	0.038	0.000	0.000	0.000
A81.1 Subacute sclerosing panencephalitis 112 Dementia, Except Alzheimer's Disease 0.096 0.038 0.000 0.000 A81.2 Progressive multifocal leukoencephalopathy 112 Dementia, Except Alzheimer's Disease 0.096 0.038 0.000 0.000 0.000 A81.8 Kuru 112 Dementia, Except Alzheimer's Disease 0.096 0.038 0.000 0.000 0.000 A81.83 Fatal familial insomia 112 Dementia, Except Alzheimer's Disease 0.096 0.038 0.000 0.000 0.000 A81.89 Other atypical virus infections of central nervous system 112 Dementia, Except Alzheimer's Disease 0.096 0.038 0.000 0.000 A81.9 Atypical virus infection of central nervous system, unspecified 155 Spinal Cord Disorders 0.094 0.080 0.053 0.000 0.010 B01.12 Varicelal myelitis 155 Spinal Cord Disorders 0.094 0.080 0.053 0.000 0.018 B02.22 Postherpetic peniculate ganglionitis 168 Tigemi	A81.Ø1	Variant Creutzfeldt-Jakob disease	112	Dementia, Except Alzheimer's Disease		0.096	0.038	0.000	0.000	0.000
A81.2 Progressive multifocal leukoencephalopathy 112 Dementia, Except Alzheimer's Disease 0.096 0.038 0.000 0.000 A81.81 Kuru 112 Dementia, Except Alzheimer's Disease 0.096 0.038 0.000 0.000 A81.82 Gerstmann-Straussler-Scheinker syndrome 112 Dementia, Except Alzheimer's Disease 0.096 0.038 0.000 0.000 A81.82 Gerstmann-Straussler-Scheinker syndrome 112 Dementia, Except Alzheimer's Disease 0.096 0.038 0.000 0.000 A81.9 Attypical virus infection of central nervous system 112 Dementia, Except Alzheimer's Disease 0.096 0.038 0.000 0.000 0.000 B00.82 Hences simplex myelitis 155 Spinal Cord Disorders 0.094 0.080 0.53 0.000 0.018 B02.12 Postherpetic geniculate ganglionitis 168 Trigeminal and Postherpetic Neuralgia 0.124 0.257 0.201 0.245 0.207 B02.24 Postherpetic mayelitis 155 Spinal Cord Disorders 0.094	A81.Ø9	Other Creutzfeldt-Jakob disease	112	Dementia, Except Alzheimer's Disease		0.096	0.038	0.000	0.000	0.000
leukoencephalopathy Image: Construct Structure	A81.1	Subacute sclerosing panencephalitis	112	Dementia, Except Alzheimer's Disease		0.096	0.038	0.000	0.000	0.000
A81.82 Gerstmann-Straussler-Scheinker syndrome 112 Dementia, Except Alzheimer's Disease 0.096 0.038 0.000 0.000 0.000 A81.83 Fatal familial insomnia 112 Dementia, Except Alzheimer's Disease 0.096 0.038 0.000 0.000 0.000 A81.89 Other atypical virus infections of central nervous system 112 Dementia, Except Alzheimer's Disease 0.096 0.038 0.000 0.000 0.000 A81.9 Atypical virus infection of central nervous system 112 Dementia, Except Alzheimer's Disease 0.096 0.038 0.000 0.000 0.000 B00.82 Herpes simplex myelitis 155 Spinal Cord Disorders 0.094 0.080 0.053 0.000 0.018 B01.12 Varicela myelitis 155 Spinal Cord Disorders 0.094 0.080 0.053 0.000 0.018 B02.23 Postherpetic geniculate ganglionitis 168 Trigeminal and Postherpetic Neuralgia 0.124 0.257 0.201 0.245 0.207 B02.24 Postherpetic myelitis	A81.2		112	Dementia, Except Alzheimer's Disease		0.096	0.038	0.000	0.000	0.000
A81.83 Fatal familial insomnia 112 Dementia, Except Alzheimer's Disease 0.096 0.038 0.000 0.000 A000 A81.89 Other atypical virus infections of central nervous system 112 Dementia, Except Alzheimer's Disease 0.096 0.038 0.000 0.000 0.000 A81.9 Atypical virus infection of central nervous system, unspecified 112 Dementia, Except Alzheimer's Disease 0.096 0.038 0.000 0.000 0.000 B00.82 Herpes simplex myelitis 155 Spinal Cord Disorders 0.094 0.080 0.053 0.000 0.000 B01.12 Varicella myelitis 155 Spinal Cord Disorders 0.094 0.080 0.053 0.000 0.018 B02.21 Postherpetic regeniculate ganglionitis 168 Trigeminal and Postherpetic Neuralgia 0.124 0.257 0.201 0.245 0.207 B02.22 Postherpetic nervous system involvement 165 Fingeninal and Postherpetic Neuralgia 0.124 0.257 0.201 0.245 0.207 B17.10 Acute hepat	A81.81	Kuru	112	Dementia, Except Alzheimer's Disease		0.096	0.038	0.000	0.000	0.000
A81.89 Other atypical virus infections of central nervous system 112 Dementia, Except Alzheimer's Disease 0.096 0.038 0.000 0.000 A81.9 Atypical virus infection of central nervous system, unspecified 112 Dementia, Except Alzheimer's Disease 0.096 0.038 0.000 0.000 0.000 B00.82 Herpes simplex myelitis 155 Spinal Cord Disorders 0.094 0.080 0.053 0.000 0.018 B01.12 Varicella myelitis 155 Spinal Cord Disorders 0.094 0.080 0.053 0.000 0.018 B02.12 Postherpetic regeniculate ganglionitis 168 Trigerninal and Postherpetic Neuralgia 0.124 0.257 0.201 0.245 0.207 B02.22 Postherpetic polyneuropathy 168 Trigerninal and Postherpetic Neuralgia 0.124 0.257 0.201 0.245 0.207 B02.24 Postherpetic nervous system 168 Frigerninal and Postherpetic Neuralgia 0.124 0.257 0.201 0.245 0.207 B02.29 Other postherpetic nervous system <td>A81.82</td> <td>Gerstmann-Straussler-Scheinker syndrome</td> <td>112</td> <td>Dementia, Except Alzheimer's Disease</td> <td></td> <td>0.096</td> <td>0.038</td> <td>0.000</td> <td>0.000</td> <td>0.000</td>	A81.82	Gerstmann-Straussler-Scheinker syndrome	112	Dementia, Except Alzheimer's Disease		0.096	0.038	0.000	0.000	0.000
nervous system Image: Constraint of central nervous 112 Dementa, Except Alzheimer's Disease 0.096 0.038 0.000 0.000 808.82 Herpes simplex myelitis 155 Spinal Cord Disorders 0.094 0.080 0.053 0.000 0.018 808.82 Herpes simplex myelitis 155 Spinal Cord Disorders 0.094 0.080 0.053 0.000 0.018 802.12 Postherpetic geniculate ganglionitis 168 Trigeminal and Postherpetic Neuralgia 0.124 0.257 0.201 0.245 0.207 802.22 Postherpetic regeniculate ganglionitis 168 Trigeminal and Postherpetic Neuralgia 0.124 0.257 0.201 0.245 0.207 802.24 Postherpetic myolyneuropathy 168 Trigeminal and Postherpetic Neuralgia 0.124 0.257 0.201 0.245 0.207 802.29 Other postherpetic nervous system 168 Trigeminal and Postherpetic Neuralgia 0.124 0.257 0.201 0.445 0.207 802.29 Other postherpetic nervous system 168	A81.83	Fatal familial insomnia	112	Dementia, Except Alzheimer's Disease		0.096	0.038	0.000	0.000	0.000
system, unspecified n	A81.89		112	Dementia, Except Alzheimer's Disease		0.096	0.038	0.000	0.000	0.000
B01.12 Varicella myelitis 155 Spinal Cord Disorders 0.094 0.080 0.053 0.000 0.018 B02.21 Postherpetic geniculate ganglionitis 168 Trigeminal and Postherpetic Neuralgia 0.124 0.257 0.201 0.245 0.207 B02.22 Postherpetic oplyneuropathy 168 Trigeminal and Postherpetic Neuralgia 0.124 0.257 0.201 0.245 0.207 B02.23 Postherpetic oplyneuropathy 168 Trigeminal and Postherpetic Neuralgia 0.124 0.257 0.201 0.245 0.207 B02.29 Other postherpetic neurous system 168 Trigeminal and Postherpetic Neuralgia 0.124 0.257 0.201 0.245 0.207 B02.29 Other postherpetic nervous system 168 Trigeminal and Postherpetic Neuralgia 0.124 0.257 0.201 0.245 0.207 B17.10 Acute hepatitis C without hepatic coma 55 Acute or Unspecified Viral Hepatitis C 0.317 0.363 0.453 0.359 0.434 B18.0 Chronic viral hepatitis S with delta-age	A81.9		112	Dementia, Except Alzheimer's Disease		0.096	0.038	0.000	0.000	0.000
B02.21 Postherpetic geniculate ganglionitis 168 Trigeminal and Postherpetic Neuralgia 0.124 0.257 0.201 0.245 0.207 B02.22 Postherpetic trigeminal neuralgia 168 Trigeminal and Postherpetic Neuralgia 0.124 0.257 0.201 0.245 0.207 B02.23 Postherpetic rolyneuropathy 168 Trigeminal and Postherpetic Neuralgia 0.124 0.257 0.201 0.245 0.207 B02.24 Postherpetic myelitis 155 Spinal Cord Disorders 0.094 0.080 0.053 0.000 0.018 B02.29 Other postherpetic nervous system involvement 168 Trigeminal and Postherpetic Neuralgia involvement 0.124 0.257 0.201 0.245 0.207 B17.10 Acute hepatitis C without hepatic coma 55 Acute or Unspecified Viral Hepatitis C 0.317 0.363 0.453 0.359 0.434 B18.0 Chronic viral hepatitis B with delta-agent 56 Chronic Viral Hepatitis B and Other Specified Chronic Viral Hepatitis B and Other Specified Chronic Viral Hepatitis C 0.307 0.443 0.748 0.446 <td>BØØ.82</td> <td>Herpes simplex myelitis</td> <td>155</td> <td>Spinal Cord Disorders</td> <td></td> <td>0.094</td> <td>0.080</td> <td>0.053</td> <td>0.000</td> <td>0.018</td>	BØØ.82	Herpes simplex myelitis	155	Spinal Cord Disorders		0.094	0.080	0.053	0.000	0.018
B02.22 Postherpetic trigeminal neuralgia 168 Trigeminal and Postherpetic Neuralgia 0.124 0.257 0.201 0.245 0.207 B02.23 Postherpetic polyneuropathy 168 Trigeminal and Postherpetic Neuralgia 0.124 0.257 0.201 0.245 0.207 B02.24 Postherpetic myelitis 155 Spinal Cord Disorders 0.094 0.080 0.053 0.000 0.018 B02.29 Other postherpetic nervous system involvement 168 Trigeminal and Postherpetic Neuralgia 0.124 0.257 0.201 0.245 0.207 B17.10 Acute hepatitis C without hepatic coma 55 Acute or Unspecified Viral Hepatitis C 0.317 0.363 0.453 0.359 0.434 B18.0 Chronic viral hepatitis B with delta-agent 56 Chronic Viral Hepatitis B and OtherSpecified Chronic Viral Hepatitis 0.307 0.443 0.748 0.446 0.170 B18.1 Chronic viral hepatitis C 54 Chronic Viral Hepatitis B and OtherSpecified Chronic Viral Hepatitis B 0.307 0.443 0.748 0.446 0.170 <	BØ1.12	Varicella myelitis	155	Spinal Cord Disorders		0.094	0.080	0.053	0.000	0.018
B02.23 Postherpetic polyneuropathy 168 Trigeminal and Postherpetic Neuralgia 0.124 0.257 0.201 0.245 0.207 B02.24 Postherpetic myelitis 155 Spinal Cord Disorders 0.094 0.080 0.053 0.000 0.018 B02.29 Other postherpetic nervous system involvement 168 Trigeminal and Postherpetic Neuralgia 0.124 0.257 0.201 0.245 0.207 B17.10 Acute hepatitis C without hepatic coma 55 Acute or Unspecified Viral Hepatitis C 0.317 0.363 0.453 0.359 0.434 B18.0 Chronic viral hepatitis C with delta-agent 56 Chronic Viral Hepatitis B and OtherSpecified Chronic Viral Hepatitis 0.307 0.443 0.748 0.446 0.170 B18.1 Chronic viral hepatitis C 54 Chronic Viral Hepatitis B and Other Specified Chronic Viral Hepatitis 0.307 0.443 0.748 0.446 0.170 B18.2 Chronic viral hepatitis C 54 Chronic Viral Hepatitis C 55 0.317 0.363 0.453 0.359 0.434	BØ2.21	Postherpetic geniculate ganglionitis	168	Trigeminal and Postherpetic Neuralgia		0.124	0.257	0.201	0.245	0.207
BØ2.24 Postherpetic myelitis 155 Spinal Cord Disorders 0.094 0.080 0.053 0.000 0.018 BØ2.29 Other postherpetic nervous system involvement 168 Trigeminal and Postherpetic Neuralgia 0.124 0.257 0.201 0.245 0.207 B17.10 Acute hepatitis C without hepatic coma 55 Acute or Unspecified Viral Hepatitis C 0.317 0.363 0.453 0.359 0.434 B17.11 Acute hepatitis C with hepatic coma 55 Acute or Unspecified Viral Hepatitis C 0.317 0.363 0.453 0.359 0.434 B18.0 Chronic viral hepatitis B with delta-agent 56 Chronic Viral Hepatitis B and OtherSpecified Chronic Viral Hepatitis 0.307 0.443 0.748 0.446 0.170 B18.2 Chronic viral hepatitis C 54 Chronic Viral Hepatitis B and Other chronic viral hepatitis C 0.307 0.443 0.748 0.446 0.170 B18.2 Unspecified viral hepatitis C without hepatic 55 Acute or Unspecified Viral Hepatitis 0.307 0.443 0.748 0.446 0.170 <td>BØ2.22</td> <td>Postherpetic trigeminal neuralgia</td> <td>168</td> <td>Trigeminal and Postherpetic Neuralgia</td> <td></td> <td>0.124</td> <td>0.257</td> <td>0.201</td> <td>0.245</td> <td>0.207</td>	BØ2.22	Postherpetic trigeminal neuralgia	168	Trigeminal and Postherpetic Neuralgia		0.124	0.257	0.201	0.245	0.207
BØ2.29 Other postherpetic nervous system involvement 168 Trigeminal and Postherpetic Neuralgia and Postherpetic Neuralgia 0.124 0.257 0.201 0.245 0.207 B17.10 Acute hepatitis C without hepatic coma 55 Acute or Unspecified Viral Hepatitis C 0.317 0.363 0.453 0.359 0.434 B17.11 Acute hepatitis C with hepatic coma 55 Acute or Unspecified Viral Hepatitis C 0.317 0.363 0.453 0.359 0.434 B18.0 Chronic viral hepatitis B with delta-agent 56 Chronic Viral Hepatitis B and OtherSpecified Chronic Viral Hepatitis 0.307 0.443 0.748 0.446 0.170 B18.1 Chronic viral hepatitis B without delta-agent 56 Chronic Viral Hepatitis B and OtherSpecified Chronic Viral Hepatitis 0.307 0.443 0.748 0.446 0.170 B18.2 Chronic viral hepatitis C 54 Chronic Viral Hepatitis C 55 0.317 0.363 0.453 0.359 0.434 B18.2 Chronic viral hepatitis C without hepatic 55 Acute or Unspecified Viral Hepatitis 0.307 0.443	BØ2.23	Postherpetic polyneuropathy	168	Trigeminal and Postherpetic Neuralgia		0.124	0.257	0.201	0.245	0.207
involvement Image: Constraint of the second se	BØ2.24	Postherpetic myelitis	155	Spinal Cord Disorders		0.094	0.080	0.053	0.000	0.018
B17.11 Acute hepatitis C with hepatic coma 55 Acute or Unspecified Viral Hepatitis C 0.317 0.363 0.453 0.359 0.434 B18.0 Chronic viral hepatitis B with delta-agent 56 Chronic Viral Hepatitis B and OtherSpecified Chronic Viral Hepatitis 0.307 0.443 0.748 0.446 0.170 B18.1 Chronic viral hepatitis B without delta-agent 56 Chronic Viral Hepatitis B and OtherSpecified Chronic Viral Hepatitis 0.307 0.443 0.748 0.446 0.170 B18.2 Chronic viral hepatitis C 54 Chronic Viral Hepatitis 0.307 0.443 0.748 0.446 0.170 B18.2 Chronic viral hepatitis C 54 Chronic Viral Hepatitis C 55 0.317 0.363 0.453 0.359 0.434 B18.2 Chronic viral hepatitis 56 Chronic Viral Hepatitis B and Other Specified Chronic Viral Hepatitis 0.307 0.443 0.748 0.446 0.170 B18.8 Other chronic viral hepatitis C without hepatic coma 55 Acute or Unspecified Viral Hepatitis C 0.317 0.363 0.453	BØ2.29		168	Trigeminal and Postherpetic Neuralgia		0.124	0.257	0.201	0.245	0.207
B18.0Chronic viral hepatitis B with delta-agent56Chronic Viral Hepatitis B and OtherSpecified Chronic Viral Hepatitis0.3070.4430.7480.4460.170B18.1Chronic viral hepatitis B without delta-agent56Chronic Viral Hepatitis B and OtherSpecified Chronic Viral Hepatitis0.3070.4430.7480.4460.170B18.2Chronic viral hepatitis C54Chronic Viral Hepatitis C550.3170.3630.4530.3590.434B18.8Other chronic viral hepatitis56Chronic Viral Hepatitis B and OtherSpecified Chronic Viral Hepatitis0.3070.4430.7480.4460.170B18.2Chronic viral hepatitis56Chronic Viral Hepatitis C550.3170.3630.4530.3590.434B18.8Other chronic viral hepatitis56Chronic Viral Hepatitis B and OtherSpecified Chronic Viral Hepatitis0.3070.4430.7480.4460.170B19.20Unspecified viral hepatitis C without hepatic coma55Acute or Unspecified Viral Hepatitis C0.3170.3630.4530.3590.434B19.21Unspecified viral hepatitis C with hepatic coma55Acute or Unspecified Viral Hepatitis C0.3170.3630.4530.3590.434B20Human immunodeficiency virus [HIV] disease1HIV/AIDS4.7595.7384.5494.7932.773B25.0Cytomegaloviral pneumonitis5Opportunistic Infections0.3370.4090.3350.262	B17.1Ø	Acute hepatitis C without hepatic coma	55	Acute or Unspecified Viral Hepatitis C		0.317	0.363	0.453	0.359	0.434
Image: constraint of the specified Chronic Viral HepatitisImage: constraint of the specified Chronic Viral HepatitisImage: constraint of the specified Chronic Viral HepatitisB18.1Chronic viral hepatitis B without delta-agent56Chronic Viral Hepatitis B and Other Specified Chronic Viral Hepatitis0.3070.4430.7480.4460.170B18.2Chronic viral hepatitis C54Chronic Viral Hepatitis C550.3170.3630.4530.3590.434B18.8Other chronic viral hepatitis56Chronic Viral Hepatitis B and OtherSpecified Chronic Viral Hepatitis0.3070.4430.7480.4460.170B19.20Unspecified viral hepatitis C without hepatic coma55Acute or Unspecified Viral Hepatitis C0.3170.3630.4530.3590.434B19.21Unspecified viral hepatitis C with hepatic coma55Acute or Unspecified Viral Hepatitis C0.3170.3630.4530.3590.434B20Human immunodeficiency virus [HIV] disease1HIV/AIDS4.7595.7384.5494.7932.773B25.0Cytomegaloviral pneumonitis5Opportunistic Infections0.3370.4090.3350.2620.270B25.2Cytomegaloviral pacreatitis5Opportunistic Infections0.3370.4090.3350.2620.270B25.8Other cytomegaloviral diseases5Opportunistic Infections0.3370.4090.3350.2620.270	B17.11	Acute hepatitis C with hepatic coma	55	Acute or Unspecified Viral Hepatitis C		0.317	0.363	0.453	0.359	0.434
Image: Chronic Viral HepatitisOther Specified Chronic Viral HepatitisImage: Chronic Viral HepatitisB18.2Chronic Viral hepatitis C54Chronic Viral Hepatitis C550.3170.3630.4530.3590.434B18.8Other chronic viral hepatitis56Chronic Viral Hepatitis B and Other Specified Chronic Viral Hepatitis0.3070.4430.7480.4460.170B19.20Unspecified viral hepatitis C without hepatic coma55Acute or Unspecified Viral Hepatitis C0.3170.3630.4530.3590.434B19.21Unspecified viral hepatitis C with hepatic coma55Acute or Unspecified Viral Hepatitis C0.3170.3630.4530.3590.434B20Human immunodeficiency virus [HIV] disease1HIV/AIDS4.7595.7384.5494.7932.773B25.0Cytomegaloviral pneumonitis5Opportunistic Infections0.3370.4090.3350.2620.270B25.2Cytomegaloviral pneumonitis5Opportunistic Infections0.3370.4090.3350.2620.270B25.8Other cytomegaloviral diseases5Opportunistic Infections0.3370.4090.3350.2620.270B25.8Other cytomegaloviral diseases5Opportunistic Infections0.3370.4090.3350.2620.270	B18.Ø	Chronic viral hepatitis B with delta-agent	56			0.307	0.443	0.748	0.446	0.170
B18.2 Chronic viral hepatitis C 54 Chronic Viral Hepatitis C 55 0.317 0.363 0.453 0.359 0.434 B18.8 Other chronic viral hepatitis 56 Chronic Viral Hepatitis B and OtherSpecified Chronic Viral Hepatitis 0.307 0.443 0.748 0.446 0.170 B19.20 Unspecified viral hepatitis C without hepatic coma 55 Acute or Unspecified Viral Hepatitis C 0.317 0.363 0.453 0.359 0.434 B19.20 Unspecified viral hepatitis C without hepatic coma 55 Acute or Unspecified Viral Hepatitis C 0.317 0.363 0.453 0.359 0.434 B19.21 Unspecified viral hepatitis C with hepatic coma 55 Acute or Unspecified Viral Hepatitis C 0.317 0.363 0.453 0.359 0.434 B20 Human immunodeficiency virus [HIV] disease 1 HIV/AIDS 4.759 5.738 4.549 4.793 2.773 B25.0 Cytomegaloviral pneumonitis 5 Opportunistic Infections 0.337 0.409 0.335 0.262 0.270 B25.	B18.1	Chronic viral hepatitis B without delta-agent	56			0.307	0.443	0.748	0.446	0.170
Image: constraint of the specified viral hepatitisOther Specified Chronic Viral HepatitisImage: constraint of the specified viral hepatitisImage: constraint of thepatitic vir	B18.2	Chronic viral hepatitis C	54		55	0.317	0.363	0.453	0.359	0.434
comacomaImage: ComaImage: ComaIma<	B18.8	Other chronic viral hepatitis	56			0.307	0.443	0.748	0.446	0.170
coma coma <thcoma< th=""> coma coma <thc< td=""><td>B19.2Ø</td><td></td><td>55</td><td>Acute or Unspecified Viral Hepatitis C</td><td></td><td>0.317</td><td>0.363</td><td>0.453</td><td>0.359</td><td>0.434</td></thc<></thcoma<>	B19.2Ø		55	Acute or Unspecified Viral Hepatitis C		0.317	0.363	0.453	0.359	0.434
diseasediseasediseasediseasediseaseB25.0Cytomegaloviral pneumonitis5Opportunistic Infections0.3370.4090.3350.2620.270B25.1Cytomegaloviral hepatitis5Opportunistic Infections0.3370.4090.3350.2620.270B25.2Cytomegaloviral pancreatitis5Opportunistic Infections0.3370.4090.3350.2620.270B25.8Other cytomegaloviral diseases5Opportunistic Infections0.3370.4090.3350.2620.270	B19.21		55	Acute or Unspecified Viral Hepatitis C		0.317	0.363	0.453	0.359	0.434
B25.1 Cytomegaloviral hepatitis 5 Opportunistic Infections 0.337 0.409 0.335 0.262 0.270 B25.2 Cytomegaloviral pancreatitis 5 Opportunistic Infections 0.337 0.409 0.335 0.262 0.270 B25.8 Other cytomegaloviral diseases 5 Opportunistic Infections 0.337 0.409 0.335 0.262 0.270	B2Ø		1	HIV/AIDS		4.759	5.738	4.549	4.793	2.773
B25.2Cytomegaloviral pancreatitis5Opportunistic Infections0.3370.4090.3350.2620.270B25.8Other cytomegaloviral diseases5Opportunistic Infections0.3370.4090.3350.2620.270	B25.Ø	Cytomegaloviral pneumonitis	5	Opportunistic Infections		0.337	0.409	0.335	0.262	0.270
B25.8Other cytomegaloviral diseases5Opportunistic Infections0.3370.4090.3350.2620.270	B25.1	Cytomegaloviral hepatitis	5	Opportunistic Infections		0.337	0.409	0.335	0.262	0.270
	B25.2	Cytomegaloviral pancreatitis	5	Opportunistic Infections		0.337	0.409	0.335	0.262	0.270
B25.9Cytomegaloviral disease, unspecified5Opportunistic Infections0.3370.4090.3350.2620.270	B25.8	Other cytomegaloviral diseases	5	Opportunistic Infections		0.337	0.409	0.335	0.262	0.270
	B25.9	Cytomegaloviral disease, unspecified	5	Opportunistic Infections		0.337	0.409	0.335	0.262	0.270

ICD-10-CM Code	ICD-10-CM Code Description	V08 RxHCC	V24 CMS-HCC Description	V08 RxHCC Hierarchy	Community Non-Low Income, Age>=65	Community Non-Low Income, Age<65	Community Low Income, Age>=65	Community Low Income, Age<65	Institutional
Z94.3	Heart and lungs transplant status	396	Heart, Lung, Liver, Intestine, or PancreasTransplant Status		0.208	0.000	0.172	0.000	0.000
Z94.4	Liver transplant status	396	Heart, Lung, Liver, Intestine, or PancreasTransplant Status		0.208	0.000	0.172	0.000	0.000
Z94.81	Bone marrow transplant status	395	Stem Cell, Including Bone Marrow, Transplant Status/Complications		2.111	1.083	2.846	1.748	1.120
Z94.82	Intestine transplant status	396	Heart, Lung, Liver, Intestine, or PancreasTransplant Status		0.208	0.000	0.172	0.000	0.000
Z94.83	Pancreas transplant status	396	Heart, Lung, Liver, Intestine, or PancreasTransplant Status		0.208	0.000	0.172	0.000	0.000
Z94.84	Stem cells transplant status	395	Stem Cell, Including Bone Marrow, Transplant Status/Complications		2.111	1.083	2.846	1.748	1.120
Z99.2	Dependence on renal dialysis		Dialysis Status, Including End StageRenal Disease	262,263	0.083	0.056	0.123	0.176	0.081
Demo	ographic Relative Factor	rs f	or Continuing Enrollee	25					

Demographic Relative Factors for Continuing Enrollees

VARIABLE	Disease Group	Community, Non-Low Income, Age≥65	Community, Non-Low Income, Age<65	Community, Low Income, Age≥65	Community, Low Income, Age<65	Institutional
Female						
0-34 Years		-	0.186		0.460	1.978
35-44 Years		-	0.323	—	0.629	2.028
45-54 Years		_	0.384	—	0.680	1.705
55-59 Years		_	0.367	—	0.615	1.538
60-64 Years		-	0.328	—	0.511	1.401
65-69 Years		0.156	_	0.347	—	1.374
70-74 Years		0.166		0.302	—	1.226
75-79 Years		0.166	—	0.252	_	1.078
80-84 Years		0.142	-	0.216	_	0.948
85-89 Years		0.123	_	0.151	—	0.831
90-94 Years		0.084	_	0.085	_	0.688
95 Years or Over			_	_	_	0.489
Male						
0-34 Years		_	0.200	—	0.498	2.005
35-44 Years		-	0.253	_	0.573	1.875
45-54 Years		_	0.305	_	0.573	1.671
55-59 Years		—	0.329	_	0.532	1.46
60-64 Years			0.334	_	0.476	1.308
65-69 Years		0.190	_	0.319	_	1.239
70-74 Years		0.177	_	0.286	_	1.088
75-79 Years		0.180	_	0.252	_	1.021
80-84 Years		0.125		0.238	_	0.936
85-89 Years		0.043	_	0.171	_	0.819
90-94 Years		_	_	0.123	_	0.7
95 Years or Over		_	—	0.046	_	0.527